These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1350604)

  • 41. In vitro activity of aztreonam against gram negative bacteria from clinical specimens and its comparison with other commonly used antibiotics.
    Qadri SM; Belobraydic KA
    Methods Find Exp Clin Pharmacol; 1986 Apr; 8(4):223-6. PubMed ID: 3088346
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Susceptibility in vitro to certain quinolines of gram-negative bacteria and gram-positive cocci causing urinary tract infections].
    Mróz E; Jankowski S; Bartelmus J; Grzybek-Hryncewicz K; Ruczkowska J; Starek J; Boratyńska M
    Med Dosw Mikrobiol; 1993; 45(1):115-8. PubMed ID: 8231429
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Highly resistant microorganisms in a teaching hospital: the role of horizontal spread in a setting of endemicity.
    Willemsen I; Mooij M; van der Wiel M; Bogaers D; van der Bijl M; Savelkoul P; Kluytmans J
    Infect Control Hosp Epidemiol; 2008 Dec; 29(12):1110-7. PubMed ID: 18973456
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Antibacterial activities of isepamicin against fresh clinical isolates of gram-negative bacilli].
    Deguchi K; Yokota N; Koguchi M; Suzuki Y; Fukayama S; Ishihara R; Oda S; Tanaka S; Nakane Y; Fukamoto T
    Jpn J Antibiot; 1994 Aug; 47(8):1053-64. PubMed ID: 7933534
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates.
    Testa R; Cantón R; Giani T; Morosini MI; Nichols WW; Seifert H; Stefanik D; Rossolini GM; Nordmann P
    Int J Antimicrob Agents; 2015 Jun; 45(6):641-6. PubMed ID: 25748553
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Activity of cefepime compared with other antibiotics against gram-positive bacteria and cefuroxime-resistant gram-negative bacteria.
    Wang FD; Liu IM; Liu CY
    Zhonghua Yi Xue Za Zhi (Taipei); 1998 Jul; 61(7):408-13. PubMed ID: 9699393
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Changes in bacterial isolates from burn wounds and their antibiograms: a 20-year study (1986-2005).
    Guggenheim M; Zbinden R; Handschin AE; Gohritz A; Altintas MA; Giovanoli P
    Burns; 2009 Jun; 35(4):553-60. PubMed ID: 19167827
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Resistance to the antimicrobial agents of bacteria isolated from non-sterile pharmaceuticals.
    de la Rosa MC; Mosso MA; García ML; Plaza C
    J Appl Bacteriol; 1993 May; 74(5):570-7. PubMed ID: 8486563
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of antimicrobial susceptibility for β-lactams against clinical isolates from 51 medical centers in Japan (2008).
    Ishii Y; Ueda C; Kouyama Y; Tateda K; Yamaguchi K
    Diagn Microbiol Infect Dis; 2011 Apr; 69(4):443-8. PubMed ID: 21396543
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An 8-year survey of strains identified in blood cultures in a clinical haematology unit.
    Bousquet A; Malfuson JV; Sanmartin N; Konopacki J; MacNab C; Souleau B; de Revel T; Elouennass M; Samson T; Soler C; Foissaud V; Martinaud C
    Clin Microbiol Infect; 2014 Jan; 20(1):O7-12. PubMed ID: 23826912
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Bacteria isolated from surgical infections and their susceptibilities to antimicrobial agents: special references to bacteria isolated between July 1996 and June 1997].
    Mashita K; Shinagawa N; Ishikawa S; Hirata K; Denno R; Mukaiya M; Mizuno A; Ishibiki K; Ushijima Y; Kinoshita H; Morimoto K; Aikawa N; Yamazaki M; Fujimoto M; Iwai S; Kato K; Tanimura H; Ohnishi H; Maeda T; Sato T; Tanaka N; Inoue F; Iwagaki H; Yura J; Tanaka S
    Jpn J Antibiot; 1999 May; 52(5):398-430. PubMed ID: 10480049
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ICU Pathogens: A Continuous Challenge.
    Hafeez A; Munir T; Najeeb S; Rehman S; Gilani M; Ansari M; Saad N
    J Coll Physicians Surg Pak; 2016 Jul; 26(7):577-80. PubMed ID: 27504548
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro activity of trovafloxacin (CP 99,219), a new fluoroquinolone against hospital isolates.
    Ling TK; Liu EY; Cheng AF
    Chemotherapy; 1999; 45(1):22-7. PubMed ID: 9876206
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative in vitro evaluation of piperacillin/tazobactam in a tertiary care hospital.
    Platsouka E; Zissis NP; Constantoulaki S; Paniara O
    J Chemother; 1997 Oct; 9(5):336-40. PubMed ID: 9373788
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ocular Pathogens and Antibiotic Sensitivity in Bacterial Keratitis Isolates at King Khaled Eye Specialist Hospital, 2011 to 2014.
    Al-Dhaheri HS; Al-Tamimi MD; Khandekar RB; Khan M; Stone DU
    Cornea; 2016 Jun; 35(6):789-94. PubMed ID: 27078003
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of the MicroScan ESBL plus confirmation panel for detection of extended-spectrum beta-lactamases in clinical isolates of oxyimino-cephalosporin-resistant Gram-negative bacteria.
    Stürenburg E; Lang M; Horstkotte MA; Laufs R; Mack D
    J Antimicrob Chemother; 2004 Nov; 54(5):870-5. PubMed ID: 15471997
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
    Nishino T; Otsuki M; Hatano K; Nishihara Y
    Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Antibacterial activities of ofloxacin against recent isolates from patients with community-acquired infections].
    Deguchi K; Yokota N; Koguchi M; Nakane Y; Suzuki Y; Fukayama S; Ishihara R; Oda S
    Jpn J Antibiot; 1991 Sep; 44(9):941-57. PubMed ID: 1960856
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antimicrobial susceptibilities of blood culture isolates obtained before and after the introduction of ciprofloxacin.
    Pieroni P; Goodfellow J; Reesor L; Louie M; Simor AE
    J Antimicrob Chemother; 1997 Mar; 39(3):419-22. PubMed ID: 9096194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.